Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.30 |
| ▸ | CHRNG | P07510 | 3/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.30 |
| ▸ | CHRND | Q07001 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.30 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393370 | 1.00 | ALDH1A1 (0.37) | ALDH1A1NPSR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26937164 | 1.00 | ALDH1A1 (0.37) | ALDH1A1NPSR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24586087 | 1.00 | ALDH1A1 (0.37) | ALDH1A1NPSR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26934638 | 1.00 | ALDH1A1 (0.37) | ALDH1A1NPSR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26934505 | 0.78 | — | — | |
| SCHEMBL26934494 | 0.73 | — | — | |
| SCHEMBL24586218 | 0.73 | ALDH1A1 (0.30) | ALDH1A1NPSR1 | |
| SCHEMBL24586221 | 0.73 | ALDH1A1 (0.30) | ALDH1A1NPSR1 | |
| SCHEMBL24586858 | 0.73 | MEN1 (0.33) | CYP3A4 | |
| SCHEMBL24586859 | 0.73 | MEN1 (0.33) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | THE BROAD INSTITUTE, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | THE BROAD INSTITUTE, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2022140677-A1 | COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BROAD INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20200045974-A1 | Substituted Oxadiazoles for Combating Phytopathogenic Fungi | BASF SE (DE) | 2020-02-13 | — | — | US | disclosed |
| US-4837218-A | CONTROLLING BRAIN DAMAGE FROM ANOXIA OR ISCHEMIA | WASHINGTON UNIVERSITY (US) | 1989-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | PHOSPHO1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GRIN2C | ALDH1A1 2435/4885NPSR1 1501/4885CHRNB2 230/4885 |
| US-20200045974-A1 | Substituted Oxadiazoles for Combating Phytopathogenic Fungi | CYP51A1, DPM1, TH | ALDH1A1 2017/4885NPSR1 2079/4885CHRNB2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.